- Home
- HLVX vs PLRX Comparison
HLVX vs PLRX Comparison
Compare HLVX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- PLRX
- Stock Information
- Founded
- HLVX 2020
- PLRX 2015
- Country
- HLVX United States
- PLRX United States
- Employees
- HLVX N/A
- PLRX N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- PLRX Health Care
- Exchange
- HLVX Nasdaq
- PLRX Nasdaq
- Market Cap
- HLVX 104.3M
- PLRX 103.7M
- IPO Year
- HLVX 2022
- PLRX 2020
- Fundamental
- Price
- HLVX $2.08
- PLRX $1.55
- Analyst Decision
- HLVX Hold
- PLRX Hold
- Analyst Count
- HLVX 1
- PLRX 10
- Target Price
- HLVX $2.00
- PLRX $3.93
- AVG Volume (30 Days)
- HLVX 829.7K
- PLRX 1.2M
- Earning Date
- HLVX 08-06-2025
- PLRX 08-07-2025
- Dividend Yield
- HLVX N/A
- PLRX N/A
- EPS Growth
- HLVX N/A
- PLRX N/A
- EPS
- HLVX N/A
- PLRX N/A
- Revenue
- HLVX N/A
- PLRX N/A
- Revenue This Year
- HLVX N/A
- PLRX N/A
- Revenue Next Year
- HLVX N/A
- PLRX N/A
- P/E Ratio
- HLVX N/A
- PLRX N/A
- Revenue Growth
- HLVX N/A
- PLRX N/A
- 52 Week Low
- HLVX $1.34
- PLRX $1.10
- 52 Week High
- HLVX $2.17
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- HLVX 52.92
- PLRX 49.79
- Support Level
- HLVX $2.07
- PLRX $1.45
- Resistance Level
- HLVX $2.10
- PLRX $1.72
- Average True Range (ATR)
- HLVX 0.04
- PLRX 0.13
- MACD
- HLVX -0.01
- PLRX -0.01
- Stochastic Oscillator
- HLVX 50.00
- PLRX 29.82
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.